Clinical data | |
---|---|
Trade names | Doral |
AHFS/Drugs.com | Monograph |
MedlinePlus | a684001 |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 29–35% |
Metabolism | Liver |
Elimination half-life | 39 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.048.329 |
Chemical and physical data | |
Formula | C17H11ClF4N2S |
Molar mass | 386.79 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Quazepam, sold under the brand name Doral among others, is a relatively long-acting benzodiazepine derivative drug developed by the Schering Corporation in the 1970s.[2] Quazepam is used for the treatment of insomnia, including sleep induction and sleep maintenance.[3] Quazepam induces impairment of motor function and has relatively (and uniquely) selective hypnotic and anticonvulsant properties with considerably less overdose potential than other benzodiazepines (due to its novel receptor-subtype selectivity).[4][5] Quazepam is an effective hypnotic which induces and maintains sleep without disruption of the sleep architecture.[6]
It was patented in 1970 and came into medical use in 1985.[7]
{{cite journal}}
: CS1 maint: overridden setting (link)